CYTK
NASDAQ
US
Cytokinetics, Incorporated - Common Stock
$66,73
▲ +$0,12
(+0,18%)
Vol. 2.5M
3
Punteggio di Qualità
fail
Ricavi ✗
Utile netto ✗
>IPO ✗
Cap. mercato
$7.8B
ROE
-131,2%
Margine
-862,2%
D/E
600,92
Beta
0,49
52W
$29–$71
Consenso Wall Street
26 analisti · Apr 20265
Acquisto forte
17
Compra
4
Mantieni
0
Vendi
0
Vendita forte
84,6%
Rating Compra
Grafico dei Prezzi
Titoli simili
Utili
Tasso di battuta: 50,0%| Trimestre | EPS Stimato | EPS Effettivo | Sorpresa |
|---|---|---|---|
| Dic 2025 | $-1,49 | $-1,50 | $-0,01 |
| Set 2025 | $-1,61 | $-2,55 | $-0,94 |
| Giu 2025 | $-1,41 | $-1,12 | +$0,29 |
| Mar 2025 | $-1,41 | $-1,39 | +$0,02 |
Ricavi e utili trimestrali
| Trimestre | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|
| Ricavi | $16.9M | $1.6M | $66.8M | $1.9M | $17.8M |
| Utile netto | -$150.0M | -$161.4M | -$134.4M | -$306.2M | -$183.0M |
Trend fondamentali
| Metrica | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | — | -132.0% | -132.0% | -132.0% | -131.2% | -131.2% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | -201.3% | -707.2% | -707.2% | -707.2% | -862.2% | -862.2% |
| Gross Margin | — | — | — | — | — | — |
| D/E Ratio | — | 603.36 | 603.36 | 603.36 | 600.92 | 600.92 |
| Current Ratio | 6.76 | 6.76 | 6.76 | 6.76 | 6.88 | 6.88 |
Rapporti chiave
ROA (TTM)
-56,5%
P/S (TTM)
89,08
P/B
15,7
EPS (TTM)
$-6,31
CF/Share
$-5,44
Crescita ricavi 3A
-36,0%
52W High
$70,98
52W Low
$29,31
$29,31
Intervallo 52 settimane
$70,98
Salute finanziaria
Flusso di cassa libero
-$148.3M
Debito netto
$1.2B
Liquidità
$122.5M
Debito totale
$1.3B
Aggiornato al Dic 31, 2025
Як CYTK виглядає на тлі конкурентів у Biotechnology?
Група порівняння: Micro-cap Biotechnology (All) · 528 компаній
Оцінка CYTK vs аналоги Biotechnology
P/E
—
▼
0%
sotto
peer
(18,8)
vs Peer
vs Settore
Sottovalutato
P/S
89,1
▲
593%
sopra
peer
(12,9)
vs Peer
vs Settore
Più costoso
P/B
15,7
▲
538%
sopra
peer
(2,5)
vs Peer
vs Settore
Sopravvalutato
Дивідендна дохідність
—
▼
0%
sotto
peer
(0,0%)
vs Peer
vs Settore
Rendimento basso
Прибутковість CYTK vs аналоги Biotechnology
ROE
-131,2%
▼
95%
sotto
peer
(-67,3%)
vs Peer
vs Settore
Debole
Net margin
-862,2%
▼
201%
sotto
peer
(-286,8%)
vs Peer
vs Settore
Debole
Валова маржа
—
▼
0%
sotto
peer
(78,6%)
vs Peer
vs Settore
In linea
ROA
-56,5%
▼
21%
sotto
peer
(-46,7%)
vs Peer
vs Settore
Sotto media
Фінансове здоровʼя CYTK vs аналоги Biotechnology
D/E ratio
600,9
▼
0%
sotto
peer
(0,0)
vs Peer
vs Settore
Debito alto
Поточна ліквідність
6,9
▲
55%
sopra
peer
(4,4)
vs Peer
vs Settore
Sotto media
Beta
0,5
▼
49%
sotto
peer
(1,0)
vs Peer
vs Settore
Più volatile
Радар фундаменталів CYTK
CYTK
Mediana peer
Industria
CYTK прибутковість vs борг
Розмір бульбашки = капіталізація · X = чиста маржа · Y = D/E ratio
CYTK vs аналоги: ключові метрики
Attività insider
NeutralAcquisti
0
Vendite
0
CALLOS ANDREW
Officer · Mar 18
1930 shs
MALIK FADY IBRAHAM
Officer · Mar 17
12033 shs
BLUM ROBERT I
Chief Executive Officer · Mar 17
36601 shs
LEE SUNG
Chief Financial Officer · Mar 17
4935 shs
CALLOS ANDREW
Officer · Mar 17
8542 shs
CALLOS ANDREW
Officer · Mar 16
1709 shs
MALIK FADY IBRAHAM
Officer · Mar 13
27306 shs
HESSEKIEL JEFFREY J
Officer · Mar 13
20646 shs
LEE SUNG
Chief Financial Officer · Mar 13
20646 shs
CALLOS ANDREW
Officer · Mar 13
33966 shs
Ultimo 90 giorni
Principali azionisti
Top 5: 54,31%T. Rowe Price Investment Ma…
14,38%
$1.1B
Blackrock Inc.
13,31%
$1.0B
FMR, LLC
10,40%
$800.5M
Vanguard Group Inc
9,78%
$753.0M
Wellington Management Group…
6,44%
$496.1M
Aggiornato al Dic 31, 2025
Ultime notizie
Nessuna notizia correlata ancora